The National Health Research Institutes (NHRI) and Molecular Targeting Technologies Inc. co-published the results of the cooperation on new anti-cancer therapeutics at the American Association for Cancer Research (AACR) meeting 2015

The National Health Research Institutes (NHRI) and Molecular Targeting Technologies Inc. make a joint statement that they will publish research results of the cooperation on novel anti-cancer therapeutics development in American Association for Cancer Research (AACR) today (US Time 2015/4/18). The developmental concept of the small molecule drug conjugate has been proved in xenograft model and the drug candidate is currently under selection. This project will proceed to clinical development toward to the next milestone.

This novel technology originated from discovering that dipicolylamine (DPA) derivatives can transport anti-cancer drugs to phosphatidylserines, tumor tissue exposed on the cell membrane efficiently and precisely.

Dr. Chuan Shih, Director of Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, said that we are glad to have an opportunity to cooperate with Molecular Targeting Technologies, Inc. (MTTI) to develop a novel anti-cancer therapeutics utilizing the unique DPA technology as transportation system.

Dr. Koon Yan Pak, President and CEO of MTTI, said that the novel anti-cancer therapeutics of DPA conjugated drugs displayed more activity and evident advantage on animal models of colorectal cancer comparing with the effect of traditional anti-cancer drugs which is heartening to us. We are investigating the effects on other cancers.

Molecular Targeting Technologies, Inc.

Molecular Targeting Technologies, Inc. (MTTI) located in West Chester, Pennsylvania, USA is a biotechnology company primarily focused on the acquisition and development of novel technologies for treatment and diagnosis of human diseases. MTTI has licensed and is developing two major technology platforms to provide: (i) novel small molecule drug conjugate (SMDC) cancer therapeutic, and (ii) in vivo imaging agents. MTTI has developed two leading product candidates, mTc-Duramycin and F-TumorVue, utilizing in vivo imaging technology platform.

Share Button

Comments are closed.